peptides
SS-31 (Elamipretide) 10mg
SS-31 (elamipretide) is a mitochondria-targeted peptide that binds cardiolipin, stabilizing mitochondrial structure and reducing oxidative stress in research models of aging, neurodegeneration, and metabolic stress.
Research-observed benefits
- ›Mitochondrial protection
- ›ATP output support
- ›Oxidative stress reduction
- ›Tissue energy preservation
Findings reported in in-vitro / preclinical research literature. Not therapeutic claims.
Reconstitution helper
Suggested: 2 mL BAC water → 5.00 mg/mL
CAS Number
—
Purity
—
Molecular Formula
—
Stock
200 units
Order type
Quantity
Research-use pricing is provided by request. with the compound name and quantity, or call 714-856-4341 for a written quote.
For in-vitro research only. Not for human consumption, diagnostic, or therapeutic use. Storage at -20°C recommended for lyophilized peptides.
SS-31 (Elamipretide) 10mg — Full Research Breakdown
Tailored information for researchers. All content is for in-vitro / preclinical research context only — not medical advice.
Mechanism of Action
Mitochondria-targeted peptide (Szeto-Schiller peptide) that binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure, preserving electron transport chain function, and reducing reactive oxygen species leakage.
How It Helps
Protects mitochondrial function under metabolic stress, improves ATP output, and reduces oxidative damage — studied in aging, neurodegeneration, cardiovascular, and metabolic disease models.
Half-Life
Plasma half-life ~1–2 hours; mitochondrial tissue retention persists longer.
Onset of Effects
Subjective energy improvements within 1–2 weeks; tissue-level markers shift over 4–8 weeks.
Administration
Subcutaneous injection, typically abdomen or thigh.
Storage
Lyophilized: –20°C, protect from light. Reconstituted: refrigerate 2–8°C, use within 28 days.
Reconstitution Guide
10 mg vial + 2 mL BAC → 5 mg/mL (0.5 mg per 0.1 mL).
Precise Dosing Protocols
Mitochondrial research
- Dose:
- 1–5 mg
- Frequency:
- Daily SC
- Duration:
- 4–12 weeks
- Notes:
- Dose escalates by research model
Age-related decline research
- Dose:
- 2–3 mg
- Frequency:
- Daily SC
- Duration:
- 12 weeks
Stacks Well With
- ›NAD+ (mitochondrial coenzyme synergy)
- ›MOTS-c (mitochondrial peptide signaling)
- ›Glutathione (oxidative stress reduction)
Research-Observed Side Effects
- •Mild injection-site reaction
- •Transient flushing
- •Occasional dizziness at higher doses
Translational Cautions
- •Pregnancy in human translational models
- •Severe renal impairment in translational studies
Cycling Guidance
4–12 weeks on, 2–4 weeks off to reassess mitochondrial markers.
Research Highlights
- ▸Birk et al. (2013): SS-31 improved mitochondrial function in aged skeletal muscle.
- ▸Karaa et al. (2018): clinical trials showed improved exercise capacity in primary mitochondrial myopathy.
- ▸Cardioprotective effects documented in ischemia-reperfusion models.